The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: GSK1120212 Rollover Study
Official Title: MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia
Study ID: NCT01376310
Brief Summary: This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Novartis Investigative Site, Goodyear, Arizona, United States
Novartis Investigative Site, Scottsdale, Arizona, United States
Novartis Investigative Site, Sacramento, California, United States
Novartis Investigative Site, Aurora, Colorado, United States
Novartis Investigative Site, New Haven, Connecticut, United States
Novartis Investigative Site, Sarasota, Florida, United States
Novartis Investigative Site, New York, New York, United States
Novartis Investigative Site, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Nashville, Tennessee, United States
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, San Antonio, Texas, United States
Novartis Investigative Site, Salt Lake City, Utah, United States
Novartis Investigative Site, Tacoma, Washington, United States
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Toulouse Cedex 9, , France
Novartis Investigative Site, Villejuif Cedex, , France
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Groningen, , Netherlands
Novartis Investigative Site, Taipei, , Taiwan
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR